Multiple Myeloma News

The Multiple Myeloma Research Foundation (MMRF) praises the Food and Drug Administration’s (FDA) decision to approve Farydak (panobinostat) for patients with advanced myeloma and treatment resistant multiple myeloma. Specifically, Farydak is approved in combination with Velcade (bortezomib) and dexamethasone for the treatment of multiple myeloma for patients who have received at least two prior standard therapies, including bortezomib and an immunomodulatory (IMiD) agent. Read More

The Multiple Myeloma Research Foundation (MMRF) today issued the following statement regarding the U.S. Food and Drug Administration’s (FDA) approval of Celgene’s REVLIMID® (Lenalidomide) in combination with dexamethasone for the treatment of newly diagnosed multiple myeloma patients who were not eligible for a stem cell transplant. Read More